Western Kentucky University

Media Relations

New Targeted Drug Helps Smokers Quit

Nicotine is absorbed rapidly through the lining of the mouth but most readily through the lungs, from where it quickly passes through the body and into the brain. Once the nicotine reaches the liver, it is metabolised by an enzyme called CYP2A6. Preliminary studies by the Canadian partner of the research project have shown that inhibitors of the nicotine-metabolising CYP2A6 enzyme can help smokers curb the need to smoke. Unfortunately, current CYP2A6 inhibitors are not viable options for anti-smoking therapy, as they involve too many adverse effects.

"We're working on developing a CYP2A6 inhibitor, a targeted drug that would only be effective in specific parts of the body. Thankfully, we have a very clear picture of the structure of CYP2A6, and we'll be able to use computer-aided modelling methods to design molecules that will bind specifically to the target without disturbing other functions in the body. We've now finished our four-year project and have discovered several molecules of an until-now-unknown structure. Along the way, we've gained new insights into how the molecules bind to the active centre of the CYP2A6 enzyme. However, it'll take a good while -- and money -- before these molecules can be developed into a targeted drug," says Hannu Raunio, the principal investigator of the research project and Professor of Pharmacology at the University of Eastern Finland.

Traditional anti-smoking therapy has long been focused on smoking cessation. At present, there are a wide variety of treatments available to help smokers quit. Nicotine, buproprion and varenicline are among the most common drugs used in the treatment of smoking addiction. The idea behind pharmaceutical nicotine products is to relieve and prevent withdrawal symptoms so as to pave the way for smoking cessation. However, such forms of treatment are often unsuccessful, which has led to suggestions that new methods are needed, methods that would help in smoking reduction. It is this type of targeted drug that Raunio's project is developing.

Source: ScienceDaily

Categories
All News  Now Viewing Category: All
School of Journalism & Broadcasting
CEBS
Media Relations
Academic Affairs
Augenstein Alumni Center
Instruments of American Excellence
Transportation
Emergency Preparedness
Police
Department of Music
Department of Theatre & Dance
Library News
Office of Sustainability
Office of International Programs
Office of Research
Ogden News
PCAL
WKU Greeks News
WKU Parent and Family Weekend
Parent's Association
Student Activities and Organizations
Scholarships Student Financial Assistance
Student Government Association News
Van Meter Auditorium
Teaching News
The Symphony at WKU
Study Abroad
Student Research Council
Student Employment
WKU Joint Admissions
International Student Office
Human Resources News
Cultural Enhancement Series
CHHS News
The Confucius Institute
Campus Activities Board
GFCB
WellU
The Carol Martin Gatton Academy of Mathematics and Science in Kentucky
Development and Alumni Relations
Downing University Center
Health Services
Hardin Planetarium
News from The Center for Gifted Studies
Student Financial Assistance
Downing Museum
Etown & Fort Knox
Facilities
Employee Wellness
Latest Headlines
Featured Articles
 Last Modified 7/23/13